Spyridon Siafis,Virginia Chiocchia,Malcolm R Macleod,Charlotte Austin,Ava Homiar,Francesca Tinsdeall,Claire Friedrich,Fiona J Ramage,Jaycee Kennett,Nobuyuki Nomura,Olena Maksym,Grazia Rutigliano,Luke J Vano,Robert A McCutcheon,David Gilbert,Edoardo G Ostinelli,Claire Stansfield,Hossein Dehdarirad,Damian Omari Juma,Simonne Wright,Ouma Simple,Olufisayo Elugbadebo,Thomy Tonia,Ioannis Mantas,Oliver D Howes,Toshi A Furukawa,Lea Milligan,Carmen Moreno,Julian H Elliott,Janna Hastings,James Thomas,Susan Michie,Emily S Sena,Soraya Seedat,Matthias Egger,Jennifer Potts,Andrea Cipriani,Georgia Salanti,Stefan Leucht

Abstract:Background: Trace amine-associated receptor 1 (TAAR1) agonism shows promise for treating psychosis, prompting us to synthesise data from human and non-human studies. Methods: We co-produced a living systematic review of controlled studies examining TAAR1 agonists in individuals (with or without psychosis/schizophrenia) and relevant animal models. Two independent reviewers identified studies in multiple electronic databases (until 17.11.2023), extracted data, and assessed risk of bias. Primary outcomes were standardised mean differences (SMD) for overall symptoms in human studies and hyperlocomotion in animal models. We also examined adverse events and neurotransmitter signalling. We synthesised data with random-effects meta-analyses. Results: Nine randomised trials provided data for two TAAR1 agonists (ulotaront and ralmitaront), and 15 animal studies for 10 TAAR1 agonists. Ulotaront and ralmitaront demonstrated few differences compared to placebo in improving overall symptoms in adults with acute schizophrenia (N=4 studies, n=1291 participants; SMD=0.15, 95%CI: -0.05, 0.34), and ralmitaront was less efficacious than risperidone (N=1, n=156, SMD=-0.53, 95%CI: -0.86, -0.20). Large placebo response was observed in ulotaront phase-III trials. Limited evidence suggested a relatively benign side-effect profile for TAAR1 agonists, although nausea and sedation were common after a single dose of ulotaront. In animal studies, TAAR1 agonists improved hyperlocomotion compared to control (N=13 studies, k=41 experiments, SMD=1.01, 95%CI: 0.74, 1.27), but seemed less efficacious compared to dopamine D 2 receptor antagonists (N=4, k=7, SMD=-0.62, 95%CI: -1.32, 0.08). Limited human and animal data indicated that TAAR1 agonists may regulate presynaptic dopaminergic signalling. Conclusions: TAAR1 agonists may be less efficacious than dopamine D 2 receptor antagonists already licensed for schizophrenia. The results are preliminary due to the limited number of drugs examined, lack of longer-term data, publication bias, and assay sensitivity concerns in trials associated with large placebo response. Considering their unique mechanism of action, relatively benign side-effect profile and ongoing drug development, further research is warranted. Registration: PROSPERO-ID: CRD42023451628.

Biological evaluation and in silico studies of novel compounds as potent TAAR1 agonists that could be used in schizophrenia treatment

Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies

Discovery of potential TAAR1 agonist targeting neurological and psychiatric disorders: An in silico approach

Structure-Based Design of Novel G-Protein-Coupled Receptor TAAR1 Agonists as Potential Antipsychotic Drug Candidates

Structural and signaling mechanisms of TAAR1 enabled preferential agonist design

Discovery and In Vivo Efficacy of Trace Amine-Associated Receptor 1 (TAAR1) Agonist 4-(2-Aminoethyl)- N-(3,5-dimethylphenyl)piperidine-1-carboxamide Hydrochloride (AP163) for the Treatment of Psychotic Disorders

Trace Amine-Associated Receptor 1 (TAAR1): A new drug target for psychiatry?

TAAR1 as an emerging target for the treatment of psychiatric disorders

Trace amine-associated receptor 1 (TAAR1) agonism for psychosis: a living systematic review and meta-analysis of human and non-human data

Current emerging therapeutic targets and clinical investigational agents for schizophrenia: Challenges and opportunities

Novel 1-Amidino-4-Phenylpiperazines as Potent Agonists at Human TAAR1 Receptor: Rational Design, Synthesis, Biological Evaluation and Molecular Docking Studies

Novel α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazole‐propionic acid receptor (AMPAR) potentiator LT‐102: A promising therapeutic agent for treating cognitive impairment associated with schizophrenia

Structure-based design of a novel third-generation antipsychotic drug lead with potential antidepressant properties

Recent Developments in the Discovery of Novel Antipsychotic Agents Modualating Dopamine and Serotonin Receptors

Up-regulation of the Trace Amine Receptor, TAAR-1, in the Prefrontal Cortex of Individuals Affected by Schizophrenia

Efficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclinical and clinical trials

Discovery of a Novel Chemo-Type for TAAR1 Agonism via Molecular Modeling

Discovery of Aryl-Piperidine Derivatives As Potential Antipsychotic Agents Using Molecular Hybridization Strategy.

In Vitro and In Vivo Characterization of PCC0104005, a Novel Modulator of Serotonin-Dopamine Activity, as an Atypical Antipsychotic Drug

Ligands of the trace amine-associated receptors (TAARs): A new class of anxiolytics

Beyond dopamine: Novel strategies for schizophrenia treatment